IL17A and breast carcinoma: A study on the effects of anti-IL-17 monoclonal antibodies on freshly resected tissues from 50 breast cancer patients suggested that targeting IL-17 may enhance breast cancer anti-tumor immune activity by inhibiting the immune checkpoint PD-L1 and suppressing MDSCs (210).